|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Laursen L: A preventable cancer. Nature.
516:S2–3. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fujiwara N, Friedman SL, Goossens N and
Hoshida Y: Risk factors and prevention of hepatocellular carcinoma
in the era of precision medicine. J Hepatol. 68:526–549. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273 e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Z, Wang C, Jiao X, Zhao S, Liu X, Wang
Y and Zhang J: miR-221 promotes growth and invasion of
hepatocellular carcinoma cells by constitutive activation of NFκB.
Am J Transl Res. 8:4764–4777. 2016.PubMed/NCBI
|
|
7
|
Wong CH, Wong CS and Chan SL: Targeting
angiogenic genes as a therapeutic approach for hepatocellular
carcinoma. Curr Gene Ther. 15:97–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu CH, Lan CH, Wu KL, Wu YM, Jane WN,
Hsiao M and Wu HC: Hepatocellular carcinoma-targeted nanoparticles
for cancer therapy. Int J Oncol. 52:389–401. 2018.PubMed/NCBI
|
|
10
|
Shi JY, Ma LJ, Zhang JW, Duan M, Ding ZB,
Yang LX, Cao Y, Zhou J, Fan J, Zhang X, et al: FOXP3 is a HCC
suppressor gene and Acts through regulating the TGF-β/Smad2/3
signaling pathway. BMC Cancer. 17:6482017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Raoul JL, Kudo M, Finn RS, Edeline J, Reig
M and Galle PR: Systemic therapy for intermediate and advanced
hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev.
68:16–24. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nada Y, Rashad N, Eissa M, Ghonaim A,
Farag K, Saadawi I, Sheha A, El Gewaity M and Abdel-Rahman O:
Outcomes of treatment with sorafenib in Egyptian patients with
hepatocellular carcinoma: A retrospective cohort study. Expert Rev
Gastroenterol Hepatol. 12:99–107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bruix J, Takayama T, Mazzaferro V, Chau
GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, et al: Adjuvant
sorafenib for hepatocellular carcinoma after resection or ablation
(STORM): A phase 3, randomised, double-blind, placebo-controlled
trial. Lancet Oncol. 16:1344–1354. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kudo M: Systemic therapy for
hepatocellular carcinoma: 2017 update. Oncology. 93 (Suppl
1):S135–S146. 2017. View Article : Google Scholar
|
|
15
|
Yuan W, Sun Y, Liu L, Zhou B, Wang S and
Gu D: Circulating lncRNAs serve as diagnostic markers for
hepatocellular carcinoma. Cell Physiol Biochem. 44:125–132. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu J, Li A, Yang J, Lu Y and Li J:
Efficacy and safety of TACE in combination with sorafenib for the
treatment of TACE-refractory advanced hepatocellular carcinoma in
Chinese patients: A retrospective study. Onco Targets Ther.
10:2761–2768. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mondal S, Bandyopadhyay S, Ghosh MK,
Mukhopadhyay S, Roy S and Mandal C: Natural products: Promising
resources for cancer drug discovery. Anticancer Agents Med Chem.
12:49–75. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu J, Zhang WD, Liu RH, Zhang C, Shen YH,
Li HL, Liang MJ and Xu XK: Benzophenanthridine alkaloids from
Zanthoxylum nitidum (Roxb.) DC, and their analgesic and
anti-inflammatory activities. Chem Biodivers. 3:990–995. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Khan H, Hadda TB and Touzani R: Diverse
therapeutic potential of nitidine, a comprehensive review. Curr
Drug Metab. 19:986–991. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fang Z, Tang Y, Jiao W, Xing Z, Guo Z,
Wang W, Shi B, Xu Z and Liu Z: Nitidine chloride inhibits renal
cancer cell metastasis via suppressing AKT signaling pathway. Food
Chem Toxicol. 60:246–251. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim LH, Khadka S, Shin JA, Jung JY, Ryu
MH, Yu HJ, Lee HN, Jang B, Yang IH, Won DH, et al: Nitidine
chloride acts as an apoptosis inducer in human oral cancer cells
and a nude mouse xenograft model via inhibition of STAT3.
Oncotarget. 8:91306–91315. 2017.PubMed/NCBI
|
|
22
|
Liao J, Xu T, Zheng JX, Lin JM, Cai QY, Yu
DB and Peng J: Nitidine chloride inhibits hepatocellular carcinoma
cell growth in vivo through the suppression of the
JAK1/STAT3 signaling pathway. Int J Mol Med. 32:79–84. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ou X, Lu Y, Liao L, Li D, Liu L, Liu H and
Xu H: Nitidine chloride induces apoptosis in human hepatocellular
carcinoma cells through a pathway involving p53, p21, Bax and
Bcl-2. Oncol Rep. 33:1264–1274. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen S, Yang L and Feng J: Nitidine
chloride inhibits proliferation and induces apoptosis in ovarian
cancer cells by activating the Fas signalling pathway. J Pharm
Pharmacol. 70:778–786. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng Z, Guo Y, Yang Y, Kan J, Dai S,
Helian M, Li B, Xu J and Liu C: Nitidine chloride suppresses
epithelial-to-mesenchymal transition in osteosarcoma cell migration
and invasion through Akt/GSK-3β/Snail signaling pathway. Oncol Rep.
36:1023–1029. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin J, Shen A, Chen H, Liao J, Xu T, Liu
L, Lin J and Peng J: Nitidine chloride inhibits hepatic cancer
growth via modulation of multiple signaling pathways. BMC Cancer.
14:7292014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Dang YW, Wang X, Yang X, Zhang R,
Lv ZL and Chen G: Comprehensive analysis of long non-coding RNA
PVT1 gene interaction regulatory network in hepatocellular
carcinoma using gene microarray and bioinformatics. Am J Transl
Res. 9:3904–3917. 2017.PubMed/NCBI
|
|
28
|
Zhang Y, He RQ, Dang YW, Zhang XL, Wang X,
Huang SN, Huang WT, Jiang MT, Gan XN, Xie Y, et al: Comprehensive
analysis of the long noncoding RNA HOXA11-AS gene interaction
regulatory network in NSCLC cells. Cancer Cell Int. 16:892016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lamb J, Crawford ED, Peck D, Modell JW,
Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et
al: The Connectivity Map: Using gene-expression signatures to
connect small molecules, genes, and disease. Science.
313:1929–1935. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 2017.
View Article : Google Scholar
|
|
31
|
Aguirre-Gamboa R, Gomez-Rueda H,
Martinez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R,
Rodriguez-Barrientos A, Tamez-Peña JG and Treviño V: SurvExpress:
An online biomarker validation tool and database for cancer gene
expression data using survival analysis. PLoS One. 8:e742502013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rao S and Mishra L: Targeting TGF-β
signaling in liver cancer. Hepatology. Dec 14–2018.(Epub ahead of
print). doi: 10.1002/hep.30426.
|
|
34
|
Liu M and Wang J, Qi Q, Huang B, Chen A,
Li X and Wang J: Nitidine chloride inhibits the malignant behavior
of human glioblastoma cells by targeting the PI3K/AKT/mTOR
signaling pathway. Oncol Rep. 36:2160–2168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim LH, Khadka S, Shin JA, Jung JY, Ryu
MH, Yu HJ, Lee HN, Jang B, Yang IH, Won DH, et al: Nitidine
chloride acts as an apoptosis inducer in human oral cancer cells
and a nude mouse xenograft model via inhibition of STAT3.
Oncotarget. 8:91306–91315. 2017.PubMed/NCBI
|
|
37
|
Wang Z, Jiang W, Zhang Z, Qian M and Du B:
Nitidine chloride inhibits LPS-induced inflammatory cytokines
production via MAPK and NF-kappaB pathway in RAW 264.7 cells. J
Ethnopharmacol. 144:145–150. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lamarca A, Mendiola M and Barriuso J:
Hepatocellular carcinoma: Exploring the impact of ethnicity on
molecular biology. Crit Rev Oncol Hematol. 105:65–72. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bupathi M, Kaseb A, Meric-Bernstam F and
Naing A: Hepatocellular carcinoma: Where there is unmet need. Mol
Oncol. 9:1501–1509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhu YJ, Zheng B, Wang HY and Chen L: New
knowledge of the mechanisms of sorafenib resistance in liver
cancer. Acta Pharmacol Sin. 38:614–622. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu L, Liao JZ, He XX and Li PY: The role
of autophagy in hepatocellular carcinoma: Friend or foe.
Oncotarget. 8:57707–57722. 2017.PubMed/NCBI
|
|
42
|
Mazzocca A, Antonaci S and Giannelli G:
The TGF-β signaling pathway as a pharmacological target in a
hepatocellular carcinoma. Curr Pharm Des. 18:4148–4154. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Neuzillet C, de Gramont A,
Tijeras-Raballand A, de Mestier L, Cros J, Faivre S and Raymond E:
Perspectives of TGF-β inhibition in pancreatic and hepatocellular
carcinomas. Oncotarget. 5:78–94. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang P, Li QJ, Feng Y, Zhang Y, Markowitz
GJ, Ning S, Deng Y, Zhao J, Jiang S, Yuan Y, et al:
TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment
promotes venous metastases of HBV-positive hepatocellular
carcinoma. Cancer Cell. 22:291–303. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li-Weber M, Palfi K, Giaisi M and Krammer
PH: Dual role of the anti-inflammatory sesquiterpene lactone:
Regulation of life and death by parthenolide. Cell Death Differ.
12:408–409. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kim SL, Park YR, Lee ST and Kim SW:
Parthenolide suppresses hypoxia-inducible factor-1alpha signaling
and hypoxia induced epithelial-mesenchymal transition in colorectal
cancer. Int J Oncol. 51:1809–1820. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang X, Chen Q, Liu J, Fan C, Wei Q, Chen
Z and Mao X: Parthenolide Promotes Differentiation of Osteoblasts
Through the Wnt/β-catenin signaling pathway in inflammatory
environments. J Interferon Cytokine Res. 37:406–414. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Carlisi D, D'Anneo A, Angileri L,
Lauricella M, Emanuele S, Santulli A, Vento R and Tesoriere G:
Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by
inducing the expression of death receptors through inhibition of
STAT3 activation. J Cell Physiol. 226:1632–1641. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu LM, Xiong DD, Lin P, Yang H, Dang YW
and Chen G: DNA topoisomerase 1 and 2A function as oncogenes in
liver cancer and may be direct targets of nitidine chloride. Int J
Oncol. 53:1897–1912. 2018.PubMed/NCBI
|
|
50
|
Li P, Yan S, Dong X, Li Z, Qiu Y, Ji C,
Zhang J, Ji M, Li W, Wang H, et al: Cell cycle arrest and apoptosis
induction activity of nitidine chloride on acute myeloid leukemia
cells. Med Chem. 14:60–66. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu N, Li P, Zang S, Liu Q, Ma D, Sun X
and Ji C: Novel agent nitidine chloride induces erythroid
differentiation and apoptosis in CML cells through c-Myc-miRNAs
axis. PLoS One. 10:e01168802015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhai H, Hu S, Liu T, Wang F, Wang X, Wu G,
Zhang Y, Sui M, Liu H and Jiang L: Nitidine chloride inhibits
proliferation and induces apoptosis in colorectal cancer cells by
suppressing the ERK signaling pathway. Mol Med Rep. 13:2536–2542.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mody K and Abou-Alfa GK: Systemic therapy
for advanced hepatocellular carcinoma in an evolving landscape.
Curr Treat Options Oncol. 20:32019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Abou-Alfa GK, Meyer T, Cheng AL,
El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park
JW, et al: Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 379:54–63. 2018. View Article : Google Scholar : PubMed/NCBI
|
